Status:
COMPLETED
Betaferon® Regulatory Post-Marketing Surveillance
Lead Sponsor:
Bayer
Conditions:
Multiple Sclerosis
Clinically Isolated System
Eligibility:
All Genders
12+ years
Brief Summary
To identify problems/questions about following items in the clinical practice using Betaferon 1. Unknown adverse event (especially serious adverse event) 2. Identification of adverse event occurred i...
Eligibility Criteria
Inclusion
- Patients with diagnosis of MS or CIS and decision taken by the physician to prescribe Betaferon
- Patients who have not participated in Betaferon regulatory Post Marketing Surveillance before.
Exclusion
- Exclusion criteria must be read in conjunction with local product information
Key Trial Info
Start Date :
April 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2012
Estimated Enrollment :
355 Patients enrolled
Trial Details
Trial ID
NCT01414816
Start Date
April 1 2008
End Date
July 1 2012
Last Update
August 21 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations, South Korea